Phase II study of S-1 and CDDP as neoadjuvant chemotherapy for patients with lymph node metastasis from resectable gastric cancer
Phase 2
- Conditions
- Resecatbele lymph node metastatic gastric cancer
- Registration Number
- JPRN-UMIN000001401
- Lead Sponsor
- ihon University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix, patients contraindicated to S-1, A history of severe drug hypersensitivity, Uncontrolled medical conditions , Documented or suspected infection, Patients requiring treatment with corticosteroids except for pre-medication, Hepatitis B or C, patients with diarrhea, Pregnant or lactating women and women of child bearing potential not using contraception, Severe psychiatric disorders, Severe edema, Grade 2 or grater peripheral neuropathy, HIV positive, patients judged by the investigator as unfit to be enrolled in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete resection rate
- Secondary Outcome Measures
Name Time Method Compliance of treatment tolerance Response rate Relapse Free Survival (3years)